Full Press Release Details
Therapeutics to Participate in Morgan Stanley's 20th Annual Global Healthcare Conference
Switzerland, September 6, 2022 - ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive Officer,
will participate in a fireside chat at Morgan Stanley's 20th Annual Global Healthcare Conference on Tuesday, September
13th at 11:45 a.m. ET.
live webcast of the presentation will be available via the Events & Presentations page in the Investors section of ADC Therapeutics'
website, ir.adctherapeutics.com. A replay of the webcast will be available
for approximately 30 days.
Therapeutics (NYSE: ADCT) is a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation,
targeted antibody drug conjugates (ADCs). The Company is advancing its proprietary PBD-based ADC technology to transform the treatment
paradigm for patients with hematologic malignancies and solid tumors.
Therapeutics' CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) is approved by the FDA for the treatment of relapsed or
refractory diffuse large b-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination
with other agents. Cami (camidanlumab tesirine) is being evaluated in a pivotal Phase 2 trial for relapsed or refractory Hodgkin lymphoma
and in a Phase 1b clinical trial for various advanced solid tumors. In addition to ZYNLONTA and Cami, ADC Therapeutics has multiple ADCs
in ongoing clinical and preclinical development.
Therapeutics is based in Lausanne (Biop le), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey.
For more information, please visit https://adctherapeutics.com/ and follow the Company on Twitter and LinkedIn.
is a registered trademark of ADC Therapeutics SA.